| Symbol | SVA |
|---|---|
| Name | SINOVAC BIOTECH LTD |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Pharmaceutical Preparations |
| Address | NO. 39 SHANGDI XI ROAD, BEIJING, None 100085 |
| Telephone | 86-10-82799800 |
| Fax | — |
| — | |
| Website | http://www.sinovac.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001084201 |
| Description | Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets. Additional info from NASDAQ: |
2026-06-17 11:00
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Read more
2026-06-15 10:00
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
Read more
2026-06-05 20:01
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
Read more
2026-06-05 10:27
New Form 20-F - SINOVAC BIOTECH LTD <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001193125-26-258534 <b>Size:</b> 31 MB
Read more
2026-05-29 20:01
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Read more
2026-05-21 10:30
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Read more
2026-04-17 07:10
New Form 3 - SINOVAC BIOTECH LTD <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001213900-26-044883 <b>Size:</b> 5 KB
Read more
2026-03-18 09:38
New Form 3 - SINOVAC BIOTECH LTD <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001213900-26-029904 <b>Size:</b> 12 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00900588 | Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine… | Phase2 | Influenza | Completed | — | — | ClinicalTrials.gov |
| NCT07611513 | Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated … | Phase3 | Hand, Foot, and Mouth Disease(HFMD) | Not_Yet_Recruiting | 2026-05-01 | 2028-09-01 | ClinicalTrials.gov |
| NCT07505823 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged… | Phase3 | Epidemic Meningitis | Not_Yet_Recruiting | 2026-03-22 | 2028-01-01 | ClinicalTrials.gov |
| NCT07505888 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged… | Phase3 | Epidemic Meningitis | Not_Yet_Recruiting | 2026-03-22 | 2026-11-01 | ClinicalTrials.gov |
| NCT07505836 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged… | Phase3 | Epidemic Meningitis | Not_Yet_Recruiting | 2026-03-22 | 2027-01-01 | ClinicalTrials.gov |
| NCT07505810 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged… | Phase3 | Epidemic Meningitis | Not_Yet_Recruiting | 2026-03-22 | 2028-01-01 | ClinicalTrials.gov |
| NCT07418229 | Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine | Phase1 | RSV | Not_Yet_Recruiting | 2026-03-09 | 2027-05-30 | ClinicalTrials.gov |
| NCT07416110 | Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies … | Phase3 | Rabies (Healthy Volunteers) | Not_Yet_Recruiting | 2026-03-04 | 2027-06-30 | ClinicalTrials.gov |
| NCT07055295 | Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exp… | Phase3 | Rabies | Not_Yet_Recruiting | 2026-03-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT07400003 | Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster … | Phase1 | Herpes Zoster | Recruiting | 2026-01-06 | 2027-04-30 | ClinicalTrials.gov |
| NCT07457060 | Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Stra… | Phase4 | Poliomyelitis | Recruiting | 2025-11-27 | 2026-10-19 | ClinicalTrials.gov |
| NCT07211152 | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women | Phase3 | Influenza | Recruiting | 2025-10-13 | 2026-06-01 | ClinicalTrials.gov |
| NCT07354269 | Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populati… | Phase4 | Poliomyelitis | Recruiting | 2025-09-26 | 2026-05-02 | ClinicalTrials.gov |
| NCT07055880 | Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Ve… | Phase2 | Rabies | Not_Yet_Recruiting | 2025-07-28 | 2026-01-15 | ClinicalTrials.gov |
| NCT06734832 | Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Va… | Phase3 | Hand, Foot, and Mouth Disease（HFMD) | Recruiting | 2024-12-13 | 2026-11-30 | ClinicalTrials.gov |
| NCT06442449 | Booster Dose of sIPV Co-administered With MMR and HepA-I. | Phase4 | Poliomyelitis | Completed | 2024-08-08 | 2025-10-10 | ClinicalTrials.gov |
| NCT06346834 | Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabi… | Phase4 | Poliomyelitis | Completed | 2024-05-20 | 2024-12-06 | ClinicalTrials.gov |
| NCT06251219 | Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Mont… | — | Hand, Foot and Mouth Disease | Unknown | 2024-02-01 | 2025-06-30 | ClinicalTrials.gov |
| NCT06183216 | A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Va… | Phase1 | Pneumococcal Infectious Disease | Completed | 2024-01-04 | 2025-03-26 | ClinicalTrials.gov |
| NCT06576024 | Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected Pe… | Phase4 | Hepatitis A | Completed | 2023-12-19 | 2025-04-25 | ClinicalTrials.gov |
| NCT06208683 | The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps V… | Phase4 | Mumps | Unknown | 2023-11-04 | 2024-12-01 | ClinicalTrials.gov |
| NCT06058416 | Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old | Phase4 | Hepatitis A | Active_Not_Recruiting | 2023-10-24 | 2029-12-31 | ClinicalTrials.gov |
| NCT06063057 | Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial | Phase1 | Hand, Foot and Mouth Disease | Completed | 2023-09-20 | 2026-03-10 | ClinicalTrials.gov |
| NCT06049927 | A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subject… | Phase3 | Seasonal Influenza | Completed | 2023-09-16 | 2024-05-23 | ClinicalTrials.gov |
| NCT06058429 | Immunogenicity of After Primary Immunization and Booster Immunization of sIPV | — | Polio | Unknown | 2023-08-16 | 2023-12-31 | ClinicalTrials.gov |
| NCT05850364 | A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinica… | Phase3 | Poliomyelitis | Completed | 2023-05-22 | 2025-02-13 | ClinicalTrials.gov |
| NCT05731115 | Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine | Phase4 | Pneumococcal Infections | Completed | 2023-02-27 | 2023-05-05 | ClinicalTrials.gov |
| NCT05156632 | Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Do… | Phase3 | COVID-19 | Withdrawn | 2023-02-20 | 2023-02-20 | ClinicalTrials.gov |
| NCT05150496 | Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Mediu… | Phase2 | COVID-19 | Suspended | 2022-12-15 | 2023-01-15 | ClinicalTrials.gov |
| NCT05637229 | A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia | — | Hand, Foot and Mouth Disease | Completed | 2022-11-28 | 2022-12-19 | ClinicalTrials.gov |
| NCT05512494 | Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inacti… | Phase4 | Seasonal Influenza | Completed | 2022-11-27 | 2023-01-24 | ClinicalTrials.gov |
| NCT05477693 | Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine | Phase4 | Pneumococcal Infections | Completed | 2022-10-25 | 2023-04-10 | ClinicalTrials.gov |
| NCT05245552 | A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 t… | Phase3 | Seasonal Influenza | Completed | 2022-08-08 | 2023-08-04 | ClinicalTrials.gov |
| NCT05397587 | An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) | Phase4 | Hand, Foot and Mouth Disease | Unknown | 2022-07-30 | 2025-10-30 | ClinicalTrials.gov |
| NCT05367895 | Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose | — | COVID-19 | Unknown | 2022-07-30 | 2023-02-15 | ClinicalTrials.gov |
| NCT05431725 | Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivate… | Phase3 | Seasonal Influenza | Completed | 2022-07-18 | 2023-07-19 | ClinicalTrials.gov |
| NCT05494047 | Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccin… | Phase3 | Influenza | Unknown | 2022-07-14 | 2023-07-31 | ClinicalTrials.gov |
| NCT07071701 | A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide… | — | Pneumococcal Infectious Disease | Completed | 2022-07-02 | 2024-04-05 | ClinicalTrials.gov |
| NCT05432141 | A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants | Phase4 | Poliomyelitis | Completed | 2022-06-13 | 2022-12-13 | ClinicalTrials.gov |
| NCT05381350 | Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cel… | Phase3 | COVID-19 | Completed | 2022-06-01 | 2023-03-09 | ClinicalTrials.gov |
| NCT05254236 | Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Mediu… | Phase2 | COVID-19 | Withdrawn | 2022-02-10 | 2022-03-10 | ClinicalTrials.gov |
| NCT05198336 | Immunogenicity of an Inactivated COVID-19 Vaccine | Phase4 | COVID-19 | Completed | 2022-01-08 | 2022-12-30 | ClinicalTrials.gov |
| NCT05166044 | Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined I… | — | Hand, Foot and Mouth Disease | Unknown | 2022-01-04 | 2022-08-10 | ClinicalTrials.gov |
| NCT05079217 | Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or Hi… | Phase4 | COVID-19 | Unknown | 2021-12-17 | 2022-06-01 | ClinicalTrials.gov |
| NCT05137418 | Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Populatio… | Phase3 | COVID-19 | Completed | 2021-11-27 | 2023-01-27 | ClinicalTrials.gov |
| NCT05471531 | Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent… | Phase4 | Influenza and Pneumonia | Completed | 2021-11-13 | 2022-07-10 | ClinicalTrials.gov |
| NCT05107557 | Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration … | Phase4 | COVID-19 | Completed | 2021-11-05 | 2022-07-14 | ClinicalTrials.gov |
| NCT04993365 | Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration … | Phase4 | COVID-19 | Completed | 2021-11-05 | 2022-07-14 | ClinicalTrials.gov |
| NCT05499351 | A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administr… | Phase4 | COVID-19 | Completed | 2021-10-15 | 2022-05-05 | ClinicalTrials.gov |
| NCT04992260 | Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Childr… | Phase3 | COVID-19 | Completed | 2021-09-10 | 2023-05-31 | ClinicalTrials.gov |
| NCT04989465 | A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine | Phase4 | Pneumococcal Infections | Completed | 2021-09-10 | 2021-09-13 | ClinicalTrials.gov |
| NCT04989231 | An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell… | — | Poliomyelitis | Completed | 2021-09-09 | 2022-12-25 | ClinicalTrials.gov |
| NCT07357545 | Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Us… | Phase3 | Rabies (Healthy Volunteers) | Completed | 2021-08-27 | 2023-06-21 | ClinicalTrials.gov |
| NCT04974164 | Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican R… | — | COVID-19 | Completed | 2021-08-17 | 2021-12-13 | ClinicalTrials.gov |
| NCT05112913 | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different W… | Phase4 | COVID-19 | Unknown | 2021-07-27 | 2023-12-25 | ClinicalTrials.gov |
| NCT04953325 | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine | Phase4 | COVID-19 | Completed | 2021-07-09 | 2022-01-31 | ClinicalTrials.gov |
| NCT04962308 | Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in … | Phase4 | COVID-19 | Unknown | 2021-06-19 | 2021-12-19 | ClinicalTrials.gov |
| NCT04911790 | Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults | Phase4 | COVID-19 | Completed | 2021-06-05 | 2023-08-31 | ClinicalTrials.gov |
| NCT04894227 | Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of C… | Phase4 | COVID-19 | Completed | 2021-05-11 | 2021-11-30 | ClinicalTrials.gov |
| NCT04801888 | Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrival… | Phase4 | COVID-19 | Completed | 2021-03-23 | 2021-05-28 | ClinicalTrials.gov |
| NCT04651790 | Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactiv… | Phase3 | Covid19 | Completed | 2020-11-27 | 2022-11-01 | ClinicalTrials.gov |
| NCT05386810 | Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants … | Phase3 | Poliomyelitis | Completed | 2020-11-05 | 2023-07-20 | ClinicalTrials.gov |
| NCT04617483 | Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among … | Phase3 | Covid19 | Completed | 2020-10-31 | 2021-05-31 | ClinicalTrials.gov |
| NCT04551547 | Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-… | Phase1 | COVID-19 | Completed | 2020-10-31 | 2023-02-08 | ClinicalTrials.gov |
| NCT04386707 | Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine | Phase3 | Poliomyelitis | Completed | 2020-05-11 | 2020-10-20 | ClinicalTrials.gov |
| NCT07026500 | Clinical Trial for Batch Consistency of EV71 Vaccine | Phase4 | EV71 Vaccine | Completed | 2019-09-19 | 2020-05-31 | ClinicalTrials.gov |
| NCT04111432 | Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Ex… | Phase4 | Hand, Foot and Mouth Disease | Completed | 2019-07-26 | 2020-03-25 | ClinicalTrials.gov |
| NCT04618783 | Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin In… | Na | Poliomyelitis | Completed | 2019-07-20 | 2020-01-10 | ClinicalTrials.gov |
| NCT04075201 | Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg) | Phase1 | Hepatitis B | Completed | 2019-07-07 | 2021-07-25 | ClinicalTrials.gov |
| NCT03903926 | Efficacy Trial of a Commercial EV71 Vaccine | Phase4 | Hand, Foot and Mouth Disease | Completed | 2019-03-26 | 2020-10-30 | ClinicalTrials.gov |
| NCT03909074 | Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-… | Phase3 | Hand, Foot and Mouth Disease | Completed | 2019-03-10 | 2019-11-13 | ClinicalTrials.gov |
| NCT03822767 | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Se… | Phase3 | Poliomyelitis | Completed | 2018-06-12 | 2018-12-11 | ClinicalTrials.gov |
| NCT03822754 | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' S… | Phase3 | Poliomyelitis | Completed | 2018-06-06 | 2018-12-11 | ClinicalTrials.gov |
| NCT03859141 | Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influe… | Phase3 | Seasonal Influenza | Completed | 2018-02-06 | 2018-11-02 | ClinicalTrials.gov |
| NCT03853993 | Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influe… | Phase3 | Seasonal Influenza | Completed | 2018-01-23 | 2018-10-08 | ClinicalTrials.gov |
| NCT03278132 | Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine | Phase4 | Hand, Foot and Mouth Disease | Completed | 2017-07-16 | 2017-09-15 | ClinicalTrials.gov |
| NCT03281174 | Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Va… | — | Hand, Foot and Mouth Disease | Completed | 2017-05-20 | 2017-05-21 | ClinicalTrials.gov |
| NCT02985320 | Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vacc… | Phase1 | Poliomyelitis | Completed | 2016-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT05065177 | Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy In… | Phase3 | Mumps | Completed | 2016-01-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02445703 | Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Com… | Phase4 | Hepatitis A | Completed | 2014-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02001233 | A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Ty… | — | Hand, Foot and Mouth Disease | Completed | 2013-03-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01736709 | The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine | Phase4 | Influenza | Completed | 2012-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01636245 | Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Entero… | Phase3 | Hand, Foot and Mouth Disease | Completed | 2012-07-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01507857 | An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine | Phase3 | Hand, Foot and Mouth Disease | Completed | 2012-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01812135 | Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in … | Phase2 | Infection, Viral, Enterovirus | Withdrawn | 2011-09-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01421121 | Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants | Phase2 | Infection, Viral, Enterovirus | Completed | 2011-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01273246 | Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children | Phase1 | Hand-foot-mouth Disease | Completed | 2011-01-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01273233 | Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults | Phase1 | Infection; Viral, Enterovirus | Completed | 2010-12-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01252680 | Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines | Phase4 | Hepatitis A | Completed | 2010-04-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01047202 | Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants | Phase4 | Influenza | Completed | 2009-12-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01008137 | Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults | Phase4 | Influenza | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00956111 | A Clinical Trial With Influenza A/H1N1 Vaccines | Phase4 | Influenza | Completed | 2009-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT01865968 | Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepa… | Phase4 | Hepatitis A | Completed | 2008-10-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00660257 | Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Vi… | Phase1 | Pandemic Influenza Vaccine | Completed | 2007-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00534885 | Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatiti… | Phase4 | Hepatitis A | Completed | 2006-03-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT00356798 | Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenz… | Phase1 | Influenza | Completed | 2005-12-01 | 2006-04-01 | ClinicalTrials.gov |
Total clinical trials: 96
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Enterovirus type EV71 vaccine (Vero cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | COMPLETED | NCT06063057 |
| high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | COMPLETED | NCT06063057 |
| medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | COMPLETED | NCT06063057 |
| low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | COMPLETED | NCT06063057 |
| Placebo | Other | Phase PHASE3 | Hand, Foot, and Mouth Disease(HFMD) | NOT_YET_RECRUITING | NCT07611513 |
| Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) | Other | Phase PHASE3 | Hand, Foot, and Mouth Disease(HFMD) | NOT_YET_RECRUITING | NCT07611513 |
| Three doses control wIPV at the schedule of 2,3,4 months of age | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT04386707 |
| Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT04386707 |
| Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT04386707 |
| Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT04386707 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell） | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04894227 |
| EV71 vaccine | Other | Preclinical | Hand, Foot and Mouth Disease | COMPLETED | NCT02001233 |
| Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE4 | Influenza and Pneumonia | COMPLETED | NCT05471531 |
| Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE4 | Influenza and Pneumonia | COMPLETED | NCT05471531 |
| Elderly group in safety observation study of combined immunization | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05499351 |
| Adult group in safety observation study of combined immunization | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05499351 |
| Elderly group in immunogenicity and safety study of combined immunization | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05499351 |
| Adult group in immunogenicity and safety study of combined immunization | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05499351 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2 | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05112913 |
| Trivalent influenza vaccine(BY) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06049927 |
| Trivalent influenza vaccine(BV) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06049927 |
| Quadrivalent influenza vaccine(0.5ml) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06049927 |
| Quadrivalent influenza vaccine(0.25ml) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06049927 |
| Placebo | Other | Phase PHASE2 | Infection, Viral, Enterovirus | COMPLETED | NCT01421121 |
| 200U EV71 vaccine without adjuvant | Other | Phase PHASE2 | Infection, Viral, Enterovirus | COMPLETED | NCT01421121 |
| 400U EV71 vaccine with adjuvant | Other | Phase PHASE2 | Infection, Viral, Enterovirus | COMPLETED | NCT01421121 |
| 200 U EV71 vaccine with adjuvant | Other | Phase PHASE2 | Infection, Viral, Enterovirus | COMPLETED | NCT01421121 |
| 100U EV71 vaccine with adjuvant | Other | Phase PHASE2 | Infection, Viral, Enterovirus | COMPLETED | NCT01421121 |
| Trivalent Inactivated Influenza Vaccine (ANFLU) | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01008137 |
| H1N1 influenza A Vaccine (PANFLU.1) | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01008137 |
| placebo | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT01636245 |
| three consecutive lots of EV71 vaccine | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT01636245 |
| Placebo | Other | Phase PHASE1 | Infection; Viral, Enterovirus | COMPLETED | NCT01273233 |
| Inactivated Enterovirus Type 71 Vaccine | Other | Phase PHASE1 | Infection; Viral, Enterovirus | COMPLETED | NCT01273233 |
| Havrix+Healive | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01252680 |
| Havrix+Havrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01252680 |
| Healive+Havrix | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01252680 |
| Healive+Healive | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01252680 |
| Seasonal trivalent vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01047202 |
| Pandemic influenza A/H1N1 vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01047202 |
| 2012-2013 trivalent seasonal influenza vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT01736709 |
| 0/0.5ml placebo | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT01507857 |
| 400U /0.5ml EV71 vaccine | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT01507857 |
| Live attenuated HAV vaccine | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01865968 |
| Inactivated HAV vaccine | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT01865968 |
| Three-dose regimen of commercialized IPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Three-dose regimen of commercialized sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Three-dose regimen of low dosage investigational sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Three-dose regimen of medium dosage investigational sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Three-dose regimen of high dosage investigational sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Single-dose regimen of medium dosage investigational sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| Single-dose regimen of high dosage investigational sIPV | Other | Phase PHASE1 | Poliomyelitis | COMPLETED | NCT02985320 |
| EV71 vaccine | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | COMPLETED | NCT03278132 |
| wIPV-bOPV-bOPV vaccination schedule | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT03822754 |
| sIPV-bOPV-bOPV vaccination schedule | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT03822754 |
| wIPV-wIPV-bOPV vaccination schedule | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT03822767 |
| sIPV-sIPV-bOPV vaccination schedule | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT03822767 |
| Trivalent influenza vaccine (contains B/Yamagata strain) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03853993 |
| Trivalent influenza vaccine (contains B/Victoria strain) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03853993 |
| Quadrivalent influenza vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03853993 |
| Trivalent influenza vaccine (contains B/Yamagata strain) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03859141 |
| Trivalent influenza vaccine (contains B/Victoria strain) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03859141 |
| Quadrivalent influenza vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT03859141 |
| Three doses of control sIPV, vaccinated within one-month interval between doses | Other | Approved | Poliomyelitis | COMPLETED | NCT04618783 |
| Three doses of control wIPV, vaccinated within one-month interval between doses | Other | Approved | Poliomyelitis | COMPLETED | NCT04618783 |
| Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses | Other | Approved | Poliomyelitis | COMPLETED | NCT04618783 |
| Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses | Other | Approved | Poliomyelitis | COMPLETED | NCT04618783 |
| Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses | Other | Approved | Poliomyelitis | COMPLETED | NCT04618783 |
| Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14. | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04801888 |
| Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28. | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04801888 |
| Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04617483 |
| Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04617483 |
| Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04617483 |
| 5000 volunteers (6-35 months)-EV71 vaccine | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | COMPLETED | NCT03903926 |
| Combined hepatitis A and hepatitis B vaccine (HABV) | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT02445703 |
| Inactivated Hepatitis A vaccine (HAV) | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT02445703 |
| Placebo | Other | Phase PHASE1 | Hand-foot-mouth Disease | COMPLETED | NCT01273246 |
| 400U inactivated Enterovirus Type 71 Vaccine | Other | Phase PHASE1 | Hand-foot-mouth Disease | COMPLETED | NCT01273246 |
| 200U inactivated Enterovirus Type 71 Vaccine | Other | Phase PHASE1 | Hand-foot-mouth Disease | COMPLETED | NCT01273246 |
| 100U inactivated Enterovirus Type 71 Vaccine | Other | Phase PHASE1 | Hand-foot-mouth Disease | COMPLETED | NCT01273246 |
| EV71 Vaccine only | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | COMPLETED | NCT04111432 |
| Single injection of EPI vaccine | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | COMPLETED | NCT04111432 |
| Concomitant administration of EV71vaccine with EPI vaccines | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | COMPLETED | NCT04111432 |
| Three doses of control vaccine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04075201 |
| Three doses of investigational vaccine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04075201 |
| One dose of control vaccine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04075201 |
| One dose of investigational vaccine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04075201 |
| 400 U EV71 vaccine with adjuvant | Other | Phase PHASE2 | Infection, Viral, Enterovirus | WITHDRAWN | NCT01812135 |
| The SARS-CoV-2 Inactivated Vaccine | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT04962308 |
| SARS-CoV-2 Inactivated Vaccine | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT04962308 |
| control live attenuated mumps vaccine | Other | Phase PHASE3 | Mumps | COMPLETED | NCT05065177 |
| Investigational live attenuated mumps vaccine | Other | Phase PHASE3 | Mumps | COMPLETED | NCT05065177 |
| Medium-dosage SARS-CoV-2 vaccine | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05079217 |
| High-dosage SARS-CoV-2 vaccine | Other | Phase PHASE4 | COVID-19 | UNKNOWN | NCT05079217 |
| Inactivated Hepatitis A Vaccine | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04953325 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04953325 |
| Inactivated COVID-19 Vaccine | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04953325 |
| 6-35 months old children-experimental EV71 vaccine. | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT03909074 |
| 36-71 months old children-control EV71 vaccine. | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT03909074 |
| 36-71 months old children-experimental EV71 vaccine. | Other | Phase PHASE3 | Hand, Foot and Mouth Disease | COMPLETED | NCT03909074 |
| Control Vaccine | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | UNKNOWN | NCT05397587 |
| Experimental Vaccine | Other | Phase PHASE4 | Hand, Foot and Mouth Disease | UNKNOWN | NCT05397587 |
| EV71 Inactivated Vaccine | Other | Preclinical | Hand, Foot and Mouth Disease | UNKNOWN | NCT05166044 |
| Tetravalent influenza vaccine developed by Sinovac Biotech Co. | Other | Phase PHASE3 | Influenza | UNKNOWN | NCT05494047 |
| High-dose COVID-19 Vaccine(Vero Cell),Inactivated | Other | Phase PHASE2 | COVID-19 | SUSPENDED | NCT05150496 |
| Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated | Other | Phase PHASE2 | COVID-19 | SUSPENDED | NCT05150496 |
| Experimental Group | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05107557 |
| Control 23-valent PPV | Other | Phase PHASE4 | Pneumococcal Infections | COMPLETED | NCT04989465 |
| Investigational 23-valent PPV | Other | Phase PHASE4 | Pneumococcal Infections | COMPLETED | NCT04989465 |
| Inactivated COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT04974164 |
| sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT05432141 |
| sIPV vaccine /DTaP vaccine | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT05432141 |
| COVID-19 Vaccine (Vero Cell), Inactivated | Other | Preclinical | COVID-19 | UNKNOWN | NCT05367895 |
| Control IPV | Other | Preclinical | Poliomyelitis | COMPLETED | NCT04989231 |
| Investigational sIPV | Other | Preclinical | Poliomyelitis | COMPLETED | NCT04989231 |
| SARS-CoV-2 inactivated vaccine | Other | Phase PHASE3 | Covid19 | COMPLETED | NCT04651790 |
| Placebo-comparator group | Other | Phase PHASE3 | COVID-19 | WITHDRAWN | NCT05156632 |
| High-dosage COVID-19 Vaccine,Inactivated | Other | Phase PHASE3 | COVID-19 | WITHDRAWN | NCT05156632 |
| Medium-dosage COVID-19 Vaccine,Inactivated | Other | Phase PHASE3 | COVID-19 | WITHDRAWN | NCT05156632 |
| Experimental 23-valent Pneumococcal | Other | Phase PHASE4 | Pneumococcal Infections | COMPLETED | NCT05731115 |
| Quadrivalent Influenza Vaccine (Split Virion), inactivated | Other | Phase PHASE4 | Seasonal Influenza | COMPLETED | NCT05512494 |
| Control 23-valent PPV | Other | Phase PHASE4 | Pneumococcal Infections | COMPLETED | NCT05477693 |
| Experimental 23-valent PPV | Other | Phase PHASE4 | Pneumococcal Infections | COMPLETED | NCT05477693 |
| COVID-19 Vaccine (Vero Cell), Inactivated (High-dose) | Other | Phase PHASE2 | COVID-19 | WITHDRAWN | NCT05254236 |
| COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose) | Other | Phase PHASE2 | COVID-19 | WITHDRAWN | NCT05254236 |
| Inactivated COVID-19 Vaccine | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT05198336 |
| Experimental Group | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04911790 |
| Two doses of placebo at the schedule of day 0,28 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04551547 |
| Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04551547 |
| Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04551547 |
| Control Group | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04993365 |
| Experimental Group | Other | Phase PHASE4 | COVID-19 | COMPLETED | NCT04993365 |
| COVID-19 Vaccine,Inactivated | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05137418 |
| Controlled vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04992260 |
| Inactivated COVID-19 Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04992260 |
| no intervention | Other | Preclinical | Polio | UNKNOWN | NCT06058429 |
| Influenza Vaccine, inactivated, quadrivlent(QIV) | Other | Phase PHASE4 | Mumps | UNKNOWN | NCT06208683 |
| Mumps vaccine, Live (MV) | Other | Phase PHASE4 | Mumps | UNKNOWN | NCT06208683 |
| PCR | Other | Preclinical | Hand, Foot and Mouth Disease | UNKNOWN | NCT06251219 |
| single-person sIPV control vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT05386810 |
| IPV control vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT05386810 |
| Experimental vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT05386810 |
| Control Quadrivalent influenza virus vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05431725 |
| Influenza Vaccine (Split Virion), Inactivated, Quadrivalent | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05431725 |
| Trivalent influenza vaccine(BY) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05245552 |
| Trivalent influenza vaccine(BV) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05245552 |
| Quadrivalent influenza vaccine(0.5ml) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05245552 |
| Quadrivalent influenza vaccine(0.25ml) | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05245552 |
| COVID-19 Vaccine (Vero cell), Inactivated (CZ strain) | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05381350 |
| COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant) | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05381350 |
| Healive (hepatitis A vacine(human diploid cell), inactivated) | Other | Phase PHASE4 | Hepatitis A | ACTIVE_NOT_RECRUITING | NCT06058416 |
| Enterovirus Type 71 Vaccine (Vero Cell), Inactivated | Other | Phase PHASE3 | Hand, Foot, and Mouth Disease（HFMD) | RECRUITING | NCT06734832 |
| bivalent enterovirus vaccine (Vero cell), inactivated | Other | Phase PHASE3 | Hand, Foot, and Mouth Disease（HFMD) | RECRUITING | NCT06734832 |
| sIPV | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT06346834 |
| EV71 Vaccine | Other | Phase PHASE4 | EV71 Vaccine | COMPLETED | NCT07026500 |
| Verorab® | Other | Phase PHASE3 | Rabies | NOT_YET_RECRUITING | NCT07055295 |
| Rabies Vaccine (Serum-free Vero Cell), Freeze-dried | Other | Phase PHASE3 | Rabies | NOT_YET_RECRUITING | NCT07055295 |
| Verorab® | Other | Phase PHASE2 | Rabies | NOT_YET_RECRUITING | NCT07055880 |
| Rabies Vaccine (Serum-free Vero Cell), Freeze-dried | Other | Phase PHASE2 | Rabies | NOT_YET_RECRUITING | NCT07055880 |
| Influenza vaccine | Other | Preclinical | Pneumococcal Infectious Disease | COMPLETED | NCT07071701 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Preclinical | Pneumococcal Infectious Disease | COMPLETED | NCT07071701 |
| Sabin Strain Inactivated Poliovirus Vaccine | Other | Phase PHASE3 | Poliomyelitis | COMPLETED | NCT05850364 |
| Placebo group | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT07400003 |
| Active-controlled vaccine B | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT07400003 |
| Active-controlled vaccine A | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT07400003 |
| High-dose experimental vaccine | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT07400003 |
| Low-dose experimental vaccine | Other | Phase PHASE1 | Herpes Zoster | RECRUITING | NCT07400003 |
| At least one dose of HAV | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT06576024 |
| 2 doses of HAV | Other | Phase PHASE4 | Hepatitis A | COMPLETED | NCT06576024 |
| HepA-I | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT06442449 |
| MMR | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT06442449 |
| sIPV | Other | Phase PHASE4 | Poliomyelitis | COMPLETED | NCT06442449 |
| Enterovirus type EV71 vaccine (Vero cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | ACTIVE_NOT_RECRUITING | NCT06063057 |
| high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | ACTIVE_NOT_RECRUITING | NCT06063057 |
| medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | ACTIVE_NOT_RECRUITING | NCT06063057 |
| low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated | Other | Phase PHASE1 | Hand, Foot and Mouth Disease | ACTIVE_NOT_RECRUITING | NCT06063057 |
| DTaP-IPV-Hib | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07354269 |
| sIPV | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07354269 |
| Marketed rabies vaccine | Other | Phase PHASE3 | Rabies (Healthy Volunteers) | COMPLETED | NCT07357545 |
| Sinovac rabies vaccine | Other | Phase PHASE3 | Rabies (Healthy Volunteers) | COMPLETED | NCT07357545 |
| Vaxigrip QIV | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07211152 |
| Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07211152 |
| PREVNAR 13 | Other | Phase PHASE1 | Pneumococcal Infectious Disease | COMPLETED | NCT06183216 |
| Sinovac PCV13 | Other | Phase PHASE1 | Pneumococcal Infectious Disease | COMPLETED | NCT06183216 |
| Sinovac rabies vaccine | Other | Phase PHASE3 | Rabies (Healthy Volunteers) | NOT_YET_RECRUITING | NCT07416110 |
| Placebo | Other | Phase PHASE1 | RSV | NOT_YET_RECRUITING | NCT07418229 |
| High-dose RSV mRNA vaccine | Other | Phase PHASE1 | RSV | NOT_YET_RECRUITING | NCT07418229 |
| Low-dose RSV mRNA vaccine | Other | Phase PHASE1 | RSV | NOT_YET_RECRUITING | NCT07418229 |
| 3sIPV | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07457060 |
| 3wIPV | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07457060 |
| 1wIPV+2sIPV | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07457060 |
| 2wIPV+1sIPV | Other | Phase PHASE4 | Poliomyelitis | RECRUITING | NCT07457060 |
| active comparator vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505888 |
| experimental vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505888 |
| Active Comparator vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505836 |
| experimental vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505836 |
| Active Comparator vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505823 |
| experimental vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505823 |
| Active Comparator vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505810 |
| experimental vaccine | Other | Phase PHASE3 | Epidemic Meningitis | NOT_YET_RECRUITING | NCT07505810 |
Total products: 206